The application covers the protection of salt forms of the compound rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis. The patent will be valid until 2042.
"We are delighted to receive the final approval for this important patent. It is an essential fundament for the future development and commercialization of rabeximod", says Carl-Magnus Högerkorp, CEO at
Contact
Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com
About
https://news.cision.com/cyxone/r/cyxone-receives-patent-approval-from-the-us-for-the-salt-forms-of-the-compound-rabeximod,c3766668
https://mb.cision.com/Main/16882/3766668/2044941.pdf
(c) 2023 Cision. All rights reserved., source